Olanzapine - Focus on the Cardiometabolic Side Effects

1. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20:389-409.10.2165/00023210-200620050-00004 Search in Google Scholar

2. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25:46-53.10.1097/00007691-200302000-00007 Search in Google Scholar

3. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998;155:921-8.10.1176/ajp.155.7.921 Search in Google Scholar

4. Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A, et al. Disposition and biotrans-formation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997;25: 81-93. Search in Google Scholar

5. Kelleher JP, Centorrino F, Albert MJ, Baldessarini RJ. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs. 2002;16:249-61.10.2165/00023210-200216040-00004 Search in Google Scholar

6. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixeddose study. Schizophr Res. 1999;40:101-14.10.1016/S0920-9964(99)00053-5 Search in Google Scholar

7. McCormack PL, Wiseman LR. Olanzapine: a review of its use in the management of bipolar disorder. Drugs. 2004;64:2709-26.10.2165/00003495-200464230-00006 Search in Google Scholar

8. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry. 2005;10:79–104.10.1038/sj.mp.4001556 Search in Google Scholar

9. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology.1996;14:97-104.10.1016/0893-133X(94)00130-R Search in Google Scholar

10. D. Vancampfort, K. Vansteelandt, C.U. Correll, A.J. Mitchell, A. De Herdt, P. Sienaert, M. Probst, M. De Hert, Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators, Am. J. Psychiatry 170 (2013) 265–274. Search in Google Scholar

11. F.C. Cohen, Entry order as a consideration for innovation strategies, Nat. Rev.Durg Discovery (2006).10.1038/nrd200916531989 Search in Google Scholar

12. M. Leonhauser, 2012. Antisychotics: multiple indications help drive growth. Pm 360 marjet watch: the essential source for pharma marketers, 1, 22–24. Search in Google Scholar

13. Davis H, Attia E. Pharmacotherapy of eating disorders. Curr Opin Psychiatry. 2017; doi: 10.1097/YCO.0000000000000358.10.1097/YCO.0000000000000358822140428806268 Search in Google Scholar

14. Lord CC, Wyler SC, Wan R, Castorena CM, Ahmed N, Mathew D, Lee S, Liu C, Elmquist JK. The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J Clin Invest. 2017. pii: 93362. doi: 10.1172/JCI93362.10.1172/JCI93362 Search in Google Scholar

15. Bymaster FP, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87–96.10.1016/0893-133X(94)00129-N Search in Google Scholar

16. Meltzer HY, Huang M. In vivo actions of atypical anti-psychotic drug on serotonergic and dopaminergic systems. Prog Brain Res. 2008;172:177–197.10.1016/S0079-6123(08)00909-6 Search in Google Scholar

17. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 2007;104(9):3456–3459.10.1073/pnas.0611417104 Search in Google Scholar

18. Bymaster FP, et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999;37(1):107–122.10.1016/S0920-9964(98)00146-7 Search in Google Scholar

19. Cooper GD, Pickavance LC, Wilding JP, Harrold JA, Halford JC, Goudie AJ. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol. 2007;21(4):405–413.10.1177/026988110606963717050655 Search in Google Scholar

20. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry. 2012;17(3):242–266.10.1038/mp.2011.10921894153 Search in Google Scholar

21. Fang F, Wang Z, Wu R, Calabrese JR, Gao K. Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder? Expert Rev Neurother. 2017;17(4):407-418.10.1080/14737175.2016.127628428005435 Search in Google Scholar

22. Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos-Robles K, Jara B. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74-85.10.1016/j.phrs.2015.07.02226218604 Search in Google Scholar

23. Himmerich H, Minkwitz J, Kirkby KC. Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants. Endocr Metab Immune Disord Drug Targets. 2015;15(4):252-60.10.2174/187153031566615062309203126100432 Search in Google Scholar

24. Datta SS, Kumar A, Wright SD, Furtado VA, Russell PS. Evidence base for using atypical antipsychotics for psychosis in adolescents. Schizophr Bull. 2014;40(2):252-4.10.1093/schbul/sbt196393209224361758 Search in Google Scholar

25. Bartoli F, Lax A, Crocamo C, Clerici M, Carrà G. Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis. Psychoneuroendocrinology. 2015;56:179-89.10.1016/j.psyneuen.2015.03.01225827962 Search in Google Scholar

26. Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. Drug Saf. 2017; doi: 10.1007/s40264-017-0543-0.10.1007/s40264-017-0543-028585153 Search in Google Scholar

27. Allison D, Mentore J, Heo M, Chandler L, Cappelleri J, Infante M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–96.10.1176/ajp.156.11.1686 Search in Google Scholar

28. RummelKluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos C, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotisc in the treatment of schizophrenia: a systematic review and meta analysis. Schizophr Res. 2010;123(2–3):225–33.10.1016/j.schres.2010.07.012295751020692814 Search in Google Scholar

29. Fuller M, Shermock K, Secic M, Grogg A. Comparative study of the development of type 2 diabetes in patients taking risperidone and olanzapine. Pharmacotherapy. 2003;23(8):1037–43.10.1592/phco.23.8.1037.3287612921249 Search in Google Scholar

30. Kessing LV, Thomsen AF, Mogensen UB, Andersen M. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010;197(4):266–71.10.1192/bjp.bp.109.07693520884948 Search in Google Scholar

31. Werner FM, Covenas R. Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Expert Opin Drug Saf. 2014;13(8):1031–42.10.1517/14740338.2014.93576124975932 Search in Google Scholar

32. Potkin SG, Phiri P, Szegedi A, et al. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis. Schizophr Res.2013;150(2–3):442–9.10.1016/j.schres.2013.08.02424075603 Search in Google Scholar

33. Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association practice guideline for the treatment of patients with schizophrenia, 2nd edn. 2004. http://psychiatryonline.org. Accessed 17 Aug 2017. Search in Google Scholar

34. Lauriello J, Lambert T, Andersen S, et al. An 8-week, doubleblind, randomized, placebo-controlled study of olanzapine longacting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69:790-799.10.4088/JCP.v69n051218452346 Search in Google Scholar

35. Dixon L, Perkins D, Calmes C. American Psychiatric Association guideline watch (September 2009): practice guideline for the treatment of patients with schizophrenia. 2009. http://psychiatryonline.org. Accessed 17 Aug 2017.10.1176/appi.books.9780890423929 Search in Google Scholar

36. De Hert M, Guiraud-Diawara A, Marre C. Comparison of metabolic syndrome incidence among schizophrenia patients treated with asenapine versus olanzapine [abstract no. 2584]. Eur Psychiatry. 2013;28(Suppl 1).10.1016/S0924-9338(13)77249-3 Search in Google Scholar

37. Simpson GM, Weiden P, Pigott T, et al. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry. 2005;162:1535-1538.10.1176/appi.ajp.162.8.153516055779 Search in Google Scholar

38. Zhang Q, Deng C, Huang XF. The role of ghrelin signalling in second-generation antipsychotic-induced weight gain. Psychoneuroendocrinology. 2013;38(11):2423-38.10.1016/j.psyneuen.2013.07.01023953928 Search in Google Scholar

39. Aguilar E, Coronas R, Caixàs A. [Metabolic syndrome in patients with schizophrenia and antipsychotic treatment]. Med Clin (Barc). 2012;139(12):542-6.10.1016/j.medcli.2012.05.02822841467 Search in Google Scholar

40. Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006; 163:1821–1825.10.1176/ajp.2006.163.10.182117012695 Search in Google Scholar

41. Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry. 2010;23(6):574-81.10.1097/YCO.0b013e32833f46c920838345 Search in Google Scholar

42. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997; 171:502–508.10.1192/bjp.171.6.5029519087 Search in Google Scholar

43. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360:225–235.10.1056/NEJMoa0806994271372419144938 Search in Google Scholar

44. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007; 298:1794–1796.10.1001/jama.298.15.179417940236 Search in Google Scholar

45. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68 (Suppl 4):8–13.10.4088/JCP.0507e13 Search in Google Scholar

46. Halpert S, McFarlane SI. When the heart and the mind collide: cardiovascular risk factors and antipsychotic use in the schizophrenic population. J Cardiometab Syndr 2009; 4:1–5.10.1111/j.1559-4572.2008.00049.x19245509 Search in Google Scholar

47. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24:62–69.10.1097/01.jcp.0000104913.75206.6214709949 Search in Google Scholar

48. Bresee LC, Majumdar SR, Patten SB, et al. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010; 117:75–82.10.1016/j.schres.2009.12.01620080392 Search in Google Scholar

49. Morissette P, Hreiche R, Mallet L, Vo D, Knaus EE, Turgeon J. Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Psychopharmacol. 2007;21(7):735-41.10.1177/026988110607266917092964 Search in Google Scholar

50. Correll CU, Frederickson AM, Kane JM, et al. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006; 67:575–583.10.4088/JCP.v67n0408 Search in Google Scholar

51. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of secondgeneration antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765–1773.10.1001/jama.2009.1549305579419861668 Search in Google Scholar

52. Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005;20(5):243-51.10.1097/01.yic.0000166405.49473.7016096514 Search in Google Scholar

53. Czekalla J, Kollack-Walker S, Beasley CM Jr. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry. 2001;62 Suppl 2:35-40. Search in Google Scholar

54. Puttegowda B, Theodore J, Basappa R, Nanjappa MC. Olanzapine Induced Dilated Cardiomyopathy. Malays J Med Sci. 2016;23(2):82-4. Search in Google Scholar

55. Belhani D, Frassati D, Mégard R, Tsibiribi P, Bui-Xuan B, Tabib A, Fanton L, Malicier D, Descotes J, Timour Q Exp Toxicol Pathol. 2006; 57(3):207-12.10.1016/j.etp.2005.09.00316410188 Search in Google Scholar

56. Kataoka H, Kajiwara H, Yano E. Psychotropic drug-associated electrocardiographic presentation of diffuse J-waves in hypothermia: case report and literature review. Heart Vessels. 2016;31(6):996-1002.10.1007/s00380-015-0646-425666953 Search in Google Scholar

57. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334–1349.10.1176/appi.ajp.161.8.133415285957 Search in Google Scholar

58. Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand. 2015;132(2):97-108.10.1111/acps.1244526016380 Search in Google Scholar

59. A. Zuddas, R. Zanni, T. Usala, Second generation antipsychotics (SGAS) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies, Eur. Neuropsychopharmacol. 21 (2011) 600–620.10.1016/j.euroneuro.2011.04.00121550212 Search in Google Scholar

60. D. Vancampfort, K. Vansteelandt, C.U. Correll, A.J. Mitchell, A. De Herdt, P. Sienaert, M. Probst, M. De Hert, Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators, Am. J. Psychiatry 170 (2013) 265–274. Search in Google Scholar